VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AIFFFirefly Neuroscience, Inc.
$1.32$21M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAIFFBalance Sheet

Firefly Neuroscience, Inc. (AIFF) Balance Sheet

6Y historyFree accessUpdated daily

The company's capital structure is increasingly fragile, with goodwill representing $5.2 million of the $10.9 million in total assets as of 2026Q1, reflecting a heavy reliance on intangible value.

AIFF Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20
Total Current Assets4.46M4.03M2.63M2.25M83K703K3.35M
Cash & Short-Term Investments3.13M2.75M1.81M2.14M58K653K1.86M
Cash Only3.13M2.75M1.81M2.14M58K653K1.86M
Short-Term Investments0000000
Accounts Receivable193K194K121K84K19K41K1.44M
Days Sales Outstanding44.2462.01408.9461.57-467.6637.86
Inventory103K108K00000
Days Inventory Outstanding50.8479.32-----
Other Current Assets00280K00027.63K
Total Non-Current Assets6.45M6.45M1.97M386K52K250K419.61K
Property, Plant & Equipment197K146K136K00188K113.57K
Fixed Asset Turnover8.89x7.82x0.79x--0.17x122.42x
Goodwill5.17M5.17M00000
Intangible Assets823K861K180K386K01K0
Long-Term Investments000000210.69K
Other Non-Current Assets254K268K1.66M052K61K95.35K
Total Assets10.91M10.48M4.6M2.64M135K953K3.77M
Asset Turnover0.13x0.11x0.02x0.19x-0.03x3.68x
Asset Growth %600.88%127.71%74.21%1856.3%-85.83%-74.75%-
Total Current Liabilities2.45M2.82M4.98M2.53M2.25M3.97M1.8M
Accounts Payable1.33M1.35M1.82M630K420K500K103.65K
Days Payables Outstanding662.25989.259.89K---3.24
Short-Term Debt00694K001.79M138.6K
Deferred Revenue (Current)943K228K13K0909K459K946.88K
Other Current Liabilities0478K827K00057.4K
Current Ratio1.82x1.43x0.53x0.89x0.04x0.18x1.86x
Quick Ratio1.78x1.39x0.53x0.89x0.04x0.18x1.86x
Cash Conversion Cycle-567.17-847.92-----
Total Non-Current Liabilities14K21K0000356.99K
Long-Term Debt000000356.99K
Capital Lease Obligations0000000
Deferred Tax Liabilities0000000
Other Non-Current Liabilities0000000
Total Liabilities2.47M2.84M4.98M2.53M2.25M3.97M2.16M
Total Debt00694K001.79M495.6K
Net Debt-3.13M-2.75M-1.12M-2.14M-58K1.14M-1.36M
Debt / Equity0.00x-----0.31x
Debt / EBITDA-0.00x-----1.17x
Net Debt / EBITDA0.37x------3.21x
Interest Coverage-234.55x-124.01x-150.57x-143.56x-5.60x-31.45x-
Total Equity8.44M7.64M-375K109K-2.11M-3.01M1.61M
Equity Growth %3224.65%2136.53%-444.04%105.16%29.96%-286.81%-
Book Value per Share0.520.57-0.060.01-0.27-0.380.20
Total Shareholders' Equity8.44M7.64M-375K109K-2.11M-3.01M1.61M
Common Stock1K1K0019K0129.04K
Retained Earnings-113.62M-111.61M-87.08M-76.62M-73.91M-67.33M-12.31M
Treasury Stock000000-930.21K
Accumulated OCI0000000
Minority Interest0000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Insufficient liquidity runway

Capital Base Erosion and Instability

As reported in financial statements, AIFF's total assets have declined from a peak of $14.9 million in 2025Q2 to $10.9 million by 2026Q1, reflecting a contraction in the balance sheet that underscores the company's ongoing struggle to maintain a stable capital foundation while funding operations.

The downward trend in total assets suggests that the company is consuming its capital base to finance persistent operating losses. Investors should monitor whether this trajectory indicates a permanent impairment of the firm's ability to scale its BNA platform without further dilutive capital injections.

Tightening Liquidity and Operational Runway

Based on the most recent quarterly data, AIFF's cash position has dwindled to $3.1 million as of 2026Q1, which, when measured against the company's historical quarterly cash burn, suggests a precarious liquidity buffer that may necessitate immediate external financing to maintain ongoing research and development activities.

While the current ratio of 1.82 appears superficially adequate, the absolute level of cash remains low relative to the company's high fixed-cost structure. This limited liquidity profile leaves little room for operational errors or delays in securing new pharmaceutical contracts.

Intangible-Heavy Asset Composition Risks

According to recent SEC filings, goodwill accounts for $5.2 million of the company's $10.9 million in total assets as of 2026Q1, indicating that nearly half of the firm's asset base is comprised of intangible value rather than tangible resources or liquid capital.

This reliance on goodwill suggests that the balance sheet is sensitive to potential impairment charges if the BNA technology fails to achieve expected commercial adoption. The minimal investment in tangible PPE further highlights the company's reliance on intellectual property as its primary, yet unproven, value driver.

Equity Quality and Retained Deficits

As indicated by the company's financial history, the accumulated deficit has ballooned to $113.6 million by 2026Q1, which severely constrains the quality of equity and reflects the substantial capital required to reach the current stage of neuroscientific development.

The persistent growth of the deficit suggests that the company has yet to achieve a self-sustaining business model, relying heavily on external equity to offset operational losses. This structure warrants further investigation into the potential for future share dilution to bridge the gap between current losses and profitability.

AIFF — Frequently Asked Questions

Quick answers to the most common questions about buying AIFF stock.

What are the total assets of Firefly Neuroscience, Inc. (AIFF)?

As of 2025, Firefly Neuroscience, Inc. (AIFF) had total assets of $10.5M including $4.0M in current assets.

How much debt does Firefly Neuroscience, Inc. (AIFF) have?

Firefly Neuroscience, Inc. (AIFF) carries total debt of $0.0M, offset by $2.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Firefly Neuroscience, Inc.?

Firefly Neuroscience, Inc. (AIFF) has total shareholders' equity (book value) of $7.6M ($0.57 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Firefly Neuroscience, Inc.'s current ratio and liquidity?

Firefly Neuroscience, Inc. (AIFF) reported a current ratio of 1.43x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.